Ophidion, Inc. is a private biotechnology company with a platform technology called the Ophidion CNS Carrier Technology (OCCT), which uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. Ophidion believes this technology can be applied to deliver therapeutics for the treatment of various CNS disorders and brain malignancies. We are currently focused on developing a pipeline to deliver gene silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease. In addition, we have an analgesia program that involves a non-opioid mechanism of action.
The platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules).
Ophidion also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population.
Ophidion owns four issued patents, two in the US and two in Japan, with a fifth about to issue in Europe and is prosecuting related US patents.